CervoMed's dementia drug fails mid-stage trial, shares slump
CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease
CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b ...
FierceBiotech21h
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial
CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...
CervoMed: Neflamapimod Phase 2b Trial In Dementia With Lewy Bodies Patients Fails To Meet Targets
CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...
CervoMed Shares Slide to All-Time Low After Study Failure
CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, ...
Hosted on MSN12d
CervoMed’s stock rises as FDA grants orphan drug status to dementia drug
The US Food and Drug Administration (FDA) has granted orphan drug designation to CervoMed’s lead investigational therapy ...
Outsourcing-pharma12d
FDA grants orphan drug designation to CervoMed’s dementia drug
The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational ...
Seeking Alpha13d
CervoMed gains as dementia therapy granted FDA orphan tag
However, a mid-stage trial for the oral investigational therapy is currently underway in early-stage dementia with Lewy bodies. CervoMed (NASDAQ:CRVO) plans to post its topline data this year ...
CervoMed's dementia drug fails to meet mid-stage trial goals
U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial. The drug, ...
Yahoo Finance13d
CervoMed’s stock rises as FDA grants orphan drug status to dementia drug
The US Food and Drug Administration (FDA) has granted orphan drug designation to CervoMed’s lead investigational therapy neflamapimod for the treatment of frontotemporal dementia, a rare ...